Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC recently entered a licensing agreement that will give MainPointe exclusive marketing rights for NEXAFED and NEXAFED Sinus in the United States and Canada. Read More »
.jpg)
Regeneron and Sanofi are set to present new data from the Phase 3 Praluent (alirocumab) injection clinical trial program at this weekend’s American College of Cardiology Scientific Sessions (ACC 17) in Washington, D.C. Read More »
Amgen’s recent Phase 3 study of the effects of Repatha on patients who receive apheresis for low-density lipoprotein cholesterol showed a promising reduction in the need for the recurring procedure. Read More »
The American Society of Health-System Pharmacists recently released “The Effective Pharmacy Preceptor,” a reference to assist pharmacists in training students and residents through experiential education techniques. Read More »
Pfizer Inc. is renewing its partnership with the Union for International Cancer Control through a grant of $530,000 for the Seeding Progress and Resources for the Cancer Community: Metastatic Breast Cancer Challenge. Read More »
Pernix Therapeutics Holdings Inc. recently announced that it has been given positive feedback on its litigation in regards to the proposed generic version of Zohydro ER with Actavis Laboratories FL Inc. Read More »
Bristol-Myers Squibb Co. and Pfizer Inc. will present eight of their abstracts at the American College of Cardiology's 66th Annual Scientific Session in Washington, D.C. March 17-19. Read More »
Amgen's results of its Repatha (evolocumab) cardiovascular outcomes trial will be released at the American College of Cardiology's 66th Annual Scientific Session, which is set to take place in Washington, D.C. March 17-19. Read More »
CVS Health has selected Epic as its new electronic health record system for its more specialized care program, CVS Specialty, which includes Accordant, a care management program available to individuals suffering from rare diseases. Read More »
Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies. Read More »
Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »
Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »
In a recent February 2017 study, by Kidney International, found that Proton Pump Inhibitors (PPIs), may cause adverse effects on the human kidney. Read More »
Immune Pharmaceuticals Inc. will broaden enrollment eligibility criteria for its 10-patient open label study of Bertilimumab in the treatment of Bullous Pemphigoid (BP) after data was compiled from three patients who completed treatment. Read More »
Teva Pharmaceutical Industries Ltd. has launched generic Pristiq 1 (desvenlafaxine) extended-release tablets in 25, 50 and 100 mg in the United States. Read More »
Walgreens and Piedmont Healthcare recently added Piedmont Healthcare clinical services at 27 retail health clinics in Walgreens throughout Atlanta. Read More »
Leaders from the health care continuum met last month in Washington, D.C. to explore methods to enhance payment and delivery methods for the private market to create better value for patients. Read More »
Synergy Pharmacy Services recently received its Pharmacy Compounding Accreditation Board accreditation, which classifies it as a company that follows the highest quality and safety standards in the industry. Read More »
Matthew Myers, president of the Campaign for Tobacco-Free Kids, recently applauded CVS Pharmacy stores for its decision to remove tobacco products from its stores and the positive results that have already stemmed from it. Read More »
According to a recent PRNewswire release, CVS Pharmacy is the first national retail pharmacy chain to remove trans fat from their store brand food products. Read More »
Alerts Sign-up
